
ADC Therapeutics Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Operational Update
(MENAFN- PR Newswire) Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Completed enrollment in LOTIS-5 Phase 3 …